ERBB2 and pancreatic neoplasm: Further, the reasoning behind our concept of utilizing the effect of pan-EGFR inhibitor in abrogating MUC4 mucin in pancreatic cancer are as follows: (i) MUC4 is oncogenic and is overexpressed in pancreatic cancer [14, 37] and (ii) MUC4 potentiates invasion, migration and metastasis of pancreatic cancer cells by interacting with EGFR family protein HER2 [7, 12, 14, 15].